Experimental gene therapy targets Hard-to-Treat cancers
NCT ID NCT00923806
First seen Feb 01, 2026 · Last updated Jun 10, 2026 · Updated 20 times
Summary
This early-phase study tested a gene therapy for people with metastatic cancer that makes a protein called CEA. Researchers took white blood cells from each patient, added a new gene to help them attack CEA-positive tumors, and infused the modified cells back after chemotherapy. Only 3 patients enrolled before the study was stopped, so we don't know if it works. The goal was to shrink tumors and check safety.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.